Central to our ongoing efforts at understanding the biology of neoplasia is the acquisition of clinical samples from patients with cancer. Samples include tumor specimens and fluid that will be aspirated from blisters (frozen and fixed) and body fluids (blood).The purpose of this protocol is to collect these samples from patients with Cutaneous T Cell Lymphoma (CTCL), in association with clinical and epidemiology data. The resulting specimen and data repository will facilitate the development of both translational and basic research projects in CTCL.
Participants will be recruited from the Cutaneous Lymphoma Clinic at the Dana-Farber Cancer Institute, Jimmy Fund clinic at the Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center. All potential participants with CTCL, will be approached by the research coordinator at the time of their appointment to the clinic.
To be eligible for screening and enrollment into the study, individuals must:
1) have a diagnosis of CTCL by a dermatologist or oncologist
2) the patient or the patient’s parent(s) or legal guardian if the patient is a child, has the ability to understand and sign consent.
The following are criteria that will result in exclusion from this study:
1) diagnosis of CTCL is questionable.
This is an automatic translation service and therefore the
Cutaneous Lymphoma Foundation is not responsible
for any potential translation inaccuracies.